Despite the large debt balance compared with its current level of cash, we expect healthy cash generation from Kenvue to meet all of its near-term financial obligations. Only $1.5 billion of debt is ...

Cristina Brennan can hear the clock ticking. At the end of the year, her 12-year-old son Tristan will no longer have free ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

However, in November 2024, the FDA proposed removing oral phenylephrine as an active ingredient in over-the-counter (OTC) nasal decongestant drug products. The FDA reviewed data and found that ...

People seem to assume that expensive branded drugs will be less likely to cause them harm than their generic counterparts, which manifests via the "nocebo effect" ...

But the drug also tightens blood vessels throughout ... GSK announced in 2023 that it planned to stop producing its popular Zyrtec-D, an antihistamine and decongestant that contains ...